Find Funding Opportunities

Purpose: The National Institutes of Health (NIH) awards individual senior level research training fellowships to experienced scientists who wish to make major changes in the direction of their research careers or who wish to broaden their scientific background by acquiring new research capabilities as independent investigators in research fields relevant to the missions of participating NIH Institutes and Centers. Mechanism of Support: This funding opportunity announcement (FOA) uses the Ruth L. Kirschstein Individual Postdoctoral National Research Service Award (NRSA) mechanism (F33). Funds Available and Anticipated Number of Awards: The total amount to be awarded by participating ICs and the number of F33 award will depend on the quality and scientific merit of the applications received, their relevance to the program priorities of the participating NIH Institutes, and the availability of funds.

The National Institute on Neurological Disorders and Stroke (NINDS) Research Education grant is a flexible and specialized mechanism designed to foster the development of neuroscience researchers through creative and innovative educational programs. The overall goal of the NINDS research training and research education programs is to ensure that highly trained scientists will make future advances that lead to a reduction in the burden of neurological disease. These research education grants will create an opportunity for medical residents and fellows to participate in an intensive 9 to 24 months of mentored research education experience during residency and fellowship years. This opportunity will include the necessary research education and training for successful competition for independent mentored research awards and will facilitate the transition from fellow/resident to clinician-scientist. In addition to collection of preliminary data to be used in future applications, participants in the program will develop laboratory research skills and the critical skills necessary to design and conduct research experiments and write competitive grant applications.

Purpose. This Funding Opportunity Announcement (FOA) invites Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) for projects to design and develop advanced tools and technologies for cerebrospinal fluid (CSF) shunts that will lead to improved clinical treatment for patients with hydrocephalus. Mechanism of Support. This FOA will utilize the STTR (R41/R42) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-206, that encourages applications under the Small Business Innovation Research (SBIR) (R43/R44) grant mechanisms. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.

Purpose. This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for projects to design and develop advanced tools and technologies for cerebrospinal fluid (CSF) shunts that will lead to improved clinical treatment for patients with hydrocephalus. Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-205, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.

Purpose. This Funding Opportunity Announcement (FOA), supported by funds provided to the NIH under the American Recovery & Reinvestment Act of 2009 (Recovery Act or ARRA), Public Law 111-5, solicits grant applications for a new initiative called Biomedical Research, Development, and Growth to Spur the Acceleration of New Technologies (BRDG-SPAN) Pilot Program (RC3). The purpose of this pilot program is to address the funding gap between promising research and development (R&D) and transitioning to the market -- often called the Valley of Death -- by contributing to the critical funding needed by applicants to pursue the next appropriate milestone(s) toward ultimate commercialization; i.e., to carry out later stage research activities necessary to that end. This program aims to accelerate the transition of research innovations and technologies toward the development of products or services that will improve human health, help advance the mission of NIH and its Institutes and Centers (ICs), and create significant value and economic stimulus. This program also aims to foster partnerships among a variety of research and development (R&D) collaborators working toward these aims. Mechanism of Support. This FOA will utilize the RC3 grant mechanism. Funds Available and Anticipated Number of Awards. Contingent upon the submission of a sufficient number of scientifically meritorious applications, NIH intends to commit at least $35 million in response to this FOA. We anticipate that at least 10 awards will be made in fiscal year 2010, pending the number and quality of applications and availability of funds. As a pilot, an evaluation will be necessary before any reissuance of this FOA; any reissuance is also predicated on funds availability. Applications received under this FOA may be given funding priority if the project is deemed to have high commercial potential to be developed into a product or service as indicated by the underserved need being addressed, the lack of alternative resources in the market and/or the applicants ability to secure funding or in-kind support from an independent third-party investor and/or strategic partner.

Purpose. This NIH Funding Opportunity Announcement (FOA), supported by funds provided to the NIH under the American Recovery & Reinvestment Act of 2009 (Recovery Act or ARRA), Public Law 111-5, invites grant applications from small business concerns that propose to accelerate innovation through high risk, high reward research and development (R&D) that has commercial potential and is relevant to the mission of the NIH. The Small Business Catalyst Award is further expected to support entrepreneurs of exceptional creativity, drawn from scientific and technological environments beyond NIH, who propose pioneering and possibly transformative approaches to addressing major biomedical or behavioral challenges with the potential for downstream commercial development. The Small Business Catalyst Award for Accelerating Innovative Research funding opportunity seeks to encourage fresh research perspectives and approaches to serve the mission of NIH. In particular, applications from small business concerns without a history of NIH Small Business Innovation Research (SBIR) or Small Business Technology Transfer (STTR) support may receive funding priority. Solicited are applications for support for projects that have the potential to generate high impact results (e.g., products, processes or services) and/or innovative research applications, research tools, techniques, devices, inventions, or methodologies. The outcomes of the research supported should have potential to lead to products that will improve public health and create significant value and economic stimulus. This FOA solicits early-stage ideas that promise to lead to major leaps forward in capabilities important to serving the mission of NIH rather than incremental improvements of existing technologies. In accord with the funding priority of this initiative to attract applicants without a history of SBIR/STTR support from NIH, the focus of the projects solicited by this FOA is on early stage technology development.

Purpose. This funding opportunity announcement (FOA) solicits new (type 1) and competitive renewal (type 2) applications for the support of Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers (MDCRCs). Successful applicants will join a network of existing Centers to foster the translation of new scientific findings and technological developments into novel treatments for the muscular dystrophies. Each Center may contain a mixture of basic, translational, or clinical research, as long as efforts are directed toward the steps required for therapeutic development, including therapeutic target identification, characterization, and validation, development of diagnostics and biomarkers to characterize or stratify patient populations, in vitro assay development, animal model development and characterization, candidate therapeutic efficacy screening, preclinical therapeutic optimization and FDA-required activities leading to an investigational new drug (IND) application, clinical infrastructure and studies in support of a clinical trial, patient-oriented natural history studies, and early stage clinical trials for one or more types of muscular dystrophy. Applicants should propose multi-disciplinary and collaborative studies that address one or more gaps in the therapeutic development pipeline for muscular dystrophy. Research problems should require substantial collaborative efforts to solve, and thus are best carried out in a center setting. Mechanism of Support. This FOA will utilize the U54 Specialized Centers Cooperative Agreement grant mechanism.

Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) that propose to develop new non-animal-based assays to assess the potency of botulinum neurotoxin type A (BoNT/A) in a Good Manufacturing Practice (GMP) commercial environment. Successful projects should have as their goal the development of a test(s) and reagents that could be used for commercial release testing of BoNT/A products. Mechanism of Support. This FOA will utilize the STTR (R41/R42) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-179, which encourages applications under the Small Business Innovation Research (SBIR) (R43/R44) grant mechanisms. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.

Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop new non-animal-based assays to assess the potency of botulinum neurotoxin type A (BoNT/A) in a Good Manufacturing Practice (GMP) commercial environment. Successful projects should have as their goal the development of a test(s) and reagents that could be used for commercial release testing of BoNT/A products. Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-178, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.

Purpose. This NIH Funding Opportunity Announcement (FOA) is supported by funds provided to the NIH under the American Recovery and Reinvestment Act of 2009 (Recovery Act or ARRA), Public Law 111-5. The purpose of the Academic Research Enhancement Award (AREA) program is to stimulate research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. These AREA grants create opportunities for scientists and institutions otherwise unlikely to participate extensively in NIH programs, to contribute to the Nation's biomedical and behavioral research effort. AREA grants are intended to support small-scale health-related research projects proposed by faculty members of eligible, domestic institutions. Mechanism of Support. This FOA will utilize the Academic Research Enhancement Award (AREA) R15 award mechanism. Funds Available and Anticipated Number of Awards. It is estimated that up to 50 awards will be made in FY 2010.The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Budget and Project Period. Applicants may request up to a total of $300,000 direct costs plus applicable Facilities and Administrative (FandA)/ indirect costs. Use the modular budget for direct cost amounts up to $250,000 and the detailed budget for direct costs amounts above $250,000. The total project period for an application submitted in response to this funding opportunity may be up to three (3) years.